{
  "url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024/regulation-2",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024/regulation-2.json",
  "legislation": "uksi/2024/248",
  "legislation_title": "The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024",
  "path": "regulation/2",
  "kind": "regulation",
  "number": "2",
  "heading": "Amendment of the Misuse of Drugs Regulations 2001",
  "text": "(1) The following amendments are made to the Misuse of Drugs Regulations 2001.\n(2) In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—\n(a) after “Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Brorphine”;\n(b) after “Bufotenine” insert “Butonitazene”;\n(c) after “Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Clonitazene”;\n(d) after “Concentrate of poppy-straw” insert “Cumyl-PeGaClone”;\n(e) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—\n“Diphenidine\nEphenidine\nEthyleneoxynitazene”;\n(f) after “Etizolam” insert—\n“Etodesnitazene (etazene)\nEtonitazene”;\n(g) after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitazene”;\n(h) after “Isopropylphenidate (IPP or IPPD)” insert “Isotonitazene”;\n(i) after “Methcathinone” insert “Methoxyphenidine”;\n(j) after “Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)” insert—\n“Metodesnitazene (metazene)\nMetonitazene”;\n(k) after “Propylphenidate” insert “Protonitazene”;\n(l) after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” insert—\n“N-Desethyl etonitazene\nN-Desethylisotonitazene\nN-Desethyl protonitazene”;\n(m) after “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)” insert—\n“N-Piperidinyl-etonitazene (etonitazepipne)\nN-Pyrrolidino-etonitazene (etoniazepyne)\nN-Pyrrolidino protonitazene”.\n(3) In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 16A, 18, 19, 20, 21, 23, 26 and 27) omit “Clonitazene” and “Etonitazene”.\n(4) In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27) after “Pyrovalerone” insert “Remimazolam”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "S.I. 2001/3998, amended by S.I. 2009/3136, 2015/231 and 2017/631. There are other amending instruments, but none are relevant."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2024/248/regulation/2",
    "retrieved_at": "2026-10-28T21:33:55.214598+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}